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Summary
 
To investigate the function of NF-
 
k
 
B RelA (p65), we generated mice deficient in this NF-
 
k
 
B
family member by homologous recombination. Mice lacking RelA showed liver degeneration
and died around embryonic day 14.5. To elucidate the role of RelA in lymphocyte develop-
ment and function, we transplanted fetal liver cells of 13.5-day embryos from heterozygote
matings into irradiated SCID mice. Within 4 weeks, both T and B cells had developed in the
SCID mice receiving 
 
relA
 
2
 
/
 
2
 
 fetal liver transplants, similar to the 
 
rel
 
A
 
1
 
/
 
1
 
 and 
 
1
 
/
 
2
 
 cases.
T cells were found to mature to Thy-1
 
1
 
/TCR
 
ab
 
1
 
/CD3
 
1
 
/CD4
 
1
 
 or CD8
 
1
 
, while B cells had
the ability to differentiate to IgM
 
1
 
/B220
 
1
 
 and to secrete immunoglobulins. However, the
secretion of IgG1 and IgA was reduced in RelA-deficient B cells. Furthermore, both T and B
cells lacking RelA showed marked reduction in proliferative responses to stimulation with Con
A, anti-CD3, anti-CD3
 
1
 
anti-CD28, LPS, anti-IgM, and PMA
 
1
 
calcium ionophore. The re-
sults indicate that RelA plays a critical role in production of specific Ig isotypes and also in sig-
nal transduction pathways for lymphocyte proliferation.
 
T
 
he NF-
 
k
 
B family of transcription factors are conserved
from flies to humans and regulate the expression of a
wide variety of cellular and viral genes (reviewed in refer-
ence 1). Biochemical and molecular characteristics of NF-
 
k
 
B
and their activation pathways have been extensively studied,
especially in terms of immune and acute phase responses.
The mammalian NF-
 
k
 
B proteins, RelA (p65), c-Rel, RelB,
p50/p105, and p52/p100, share the “rel” homology domain
which facilitates dimerization, nuclear translocation and DNA
binding. Transactivation domains are also present at the
COOH termini of RelA, c-Rel, and RelB. These NF-
 
k
 
B
proteins form multiple interchangeable heterodimers and
homodimers and their activity is regulated by binding of
I
 
k
 
B inhibitory factors which determine the localization of
NF-
 
k
 
B dimers, either in the cytoplasm or in the nucleus.
Upon activation, NF-
 
k
 
B dimers dissociate from I
 
k
 
B and
translocate to the nucleus and then bind to the 
 
k
 
B sites in
promoters and enhancers of NF-
 
k
 
B responsive genes, con-
sequently activating their transcription.
The RelA/p50 heterodimer was the original NF-
 
k
 
B
identified, as a transcription factor for Ig
 
k
 
 light chain gene
(2), and has the strongest transactivating capacity among
NF-
 
k
 
B dimers as well as the most widely distributed 
 
k
 
B
binding activity (3). In the B cell lineage, RelA/p50 is the
major NF-
 
k
 
B in pre-B cells, while c-Rel/p50 is predomi-
nant in mature B cells and RelB/p52 in plasmacytomas and
LPS-activated B cells (4). This suggests that RelA/p50
plays an important role in certain steps of B cell develop-
ment, although genes regulated by RelA/p50 have yet to
be identified. In the T cell lineage, RelA/p50 has been re-
ported to be critical for antigen activation (5) and cytokine
production (3). Studies in vitro have suggested that RelA/
p50 regulates expression of the T cell receptor 
 
b
 
 chain
gene (6), cytokine genes such as IL-2 (7), IL-6 (8), and
TNF
 
a
 
 (9), and the IL-2 receptor 
 
a
 
 chain gene (10). How-
ever, because of the presence of several related proteins and
their pleiotropic effects, the specific roles of RelA in vivo
remain to be elucidated. Studies on the functions of other
NF-
 
k
 
B proteins have faced similar problems. To overcome
this drawback, mutant mice lacking RelA (11), c-Rel (12),
RelB (13), p50 (14), or I
 
k
 
B
 
a
 
 (15) have been derived by
homologous recombination to assess specific functions of
individual NF-
 
k
 
B proteins. All except RelA-deficient mice
demonstrate normal birth and development but with cer-
tain abnormalities in immune responses. In the case of RelA
deficiency, however, embryonic mortality occurs, concomi-
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tant with liver degeneration (11), so that clarification of the
function of this family member in the immune system has
faced difficulties.
In the present study, we generated RelA-deficient mice
with a targeting vector expected to yield a null mutation,
different from the vector used in the previous study which
would be expected to produce a truncated form of RelA
(11). Our RelA-deficient mice also died during embryogene-
sis but in an attempt to explore the role of RelA in lym-
phoid development, we transplanted the fetal liver cells from
 
relA
 
2
 
/
 
2
 
 embryos into SCID mice and found that the
RelA-deficient stem cells could then differentiate to ma-
ture T and B cells. To investigate the roles of RelA further,
we examined RelA-deficient T and B cells for their func-
tions and their proliferative responses to various stimuli.
 
Materials and Methods
 
Construction of the Targeting Vector.
 
The mouse 
 
relA
 
 gene was
isolated from a C57BL/6 (B6)
 
1
 
 mouse genomic library using a
mouse 
 
relA
 
 cDNA probe (codons 185-277, reference 16). The
targeting vector was constructed in pBluescript as shown in Fig. 1.
It contained 7 kb of the mouse 
 
relA
 
 gene including exons 1 to 6,
 
PMC1-neo
 
 inserted into the first exon of 
 
relA
 
 at an NcoI site 3 bp
downstream of the translation initiation codon, and the herpes
simplex virus-thymidine kinase gene (
 
HSV-tk
 
) flanking at the 3
 
9
 
end of the 
 
relA
 
 sequence. We expected that this targeting vector
would generate a null mutant allele by homologous recombina-
tion.
 
Derivation of relA-deficient Mice.
 
20 
 
m
 
g DNA of the targeting
vector was transfected into 5 
 
3
 
 10
 
7
 
 CCE embryonic stem (ES)
cells (kindly provided by Dr. Motoya Katsuki, Institute of Medi-
cal Science, University of Tokyo, Tokyo, Japan [17]) by electro-
poration (T-300; Biotechnologies & Experimental Research Inc.,
San Diego, CA). Transfected cells were cultured for 10 d in posi-
tive-negative selection medium (18) containing G418 (400 
 
m
 
g/ml;
Sigma Chem. Co., St. Louis, MO) and Gancyclovir (5 
 
m
 
M, Demo-
sine; F. Hoffmann-La Roche Ltd., Palo Alto, CA, provided by
Tanabe Seiyaku Co. Ltd., Osaka, Japan). Growing colonies were
tested for homologous recombination by DNA blot analysis using
5
 
9
 
 and 3
 
9
 
 flanking region probes. Eight clones with the targeted
allele were obtained and injected into B6 blastocysts. The blasto-
cysts were then transferred into the uterus of pseudopregnant Jcl:
MCH(ICR) (MCH) mice. Three clones produced chimeric mice
which transmitted a mutant allele to offspring by mating with B6
mice. Three 
 
relA
 
 mutant mouse strains, RKO-1, -2, and -3, were
maintained by brother-sister mating of heterozygous mice in our
animal facility. All three strains showed identical phenotypes and
RKO-1 mice were mainly used in this study. B6 and MCH mice
were purchased from Japan SLC Inc. (Hamamatsu, Japan) and
Clea Japan Inc. (Tokyo, Japan), respectively.
 
DNA and RNA Blot Analyses.
 
DNA and total RNA were
isolated using the proteinase K/SDS and the guanidium thiocyan-
ate/CsCl procedures, respectively (19, 20). DNA was digested by
restriction enzymes and separated by agarose gel electrophoresis
and then transferred to nitrocellulose filters (Schleicher & Schuell,
Dassel, Germany). Total RNA was separated by 2.2 M formalde-
hyde agarose gel electrophoresis and transferred to nitrocellulose
filters. RNA blots were analyzed by cDNA probes for 
 
relA
 
, c-
 
rel
 
(codons 144-277, reference 21), 
 
p50
 
 (codons 391-518, reference
22) and 
 
relB
 
 cDNA (codons 458-580, reference 23). DNA blots
were analyzed with 5
 
9
 
 and 3
 
9
 
 flanking region probes (see Fig. 1).
 
Immunohistochemistry and Histology.
 
Whole embryos were fixed
in buffered formalin and embedded in paraffin. Sagittal sections (5
 
m
 
m) were reacted with rabbit anti-RelA specific antibody (no. 
 
sc
 
-
372; Santa Cruz Biotechnology Inc., Santa Cruz, CA) and bind-
ing sites were visualized by an avidin-biotin enzyme complex
(ABC) method (Vectastain 
 
Elite
 
 ABC kit; Vector Laboratories Inc.,
Burlingame, CA), and then counterstained in hematoxylin. For
histological examination, the sections were stained also with he-
matoxylin-eosin (HE).
 
Transplantation of Fetal Liver Cells.
 
SCID mice between 5–8
wk age were irradiated (2.5 Gy; Hitachi MBR-1520R; Hitachi,
Tokyo) and each injected intravenously with 3 
 
3
 
 10
 
6
 
 fetal liver
cells from ED13.5 
 
relA
 
1
 
/
 
1
 
, 
 
1
 
/
 
2
 
, or 
 
2
 
/
 
2
 
 embryos. 4 wk after
the transplantation, these mice were used for experiments. SCID
mice contain very few lymphocytes in the thymus, spleen and
lymph nodes (24), due to a defect in the gene coding for DNA-
dependent protein kinase p350 (25). SCID mice were maintained
in our breeding colony.
 
Serological Analysis.
 
Two-color analysis of cell surface anti-
gens was performed with a FACScan
 
Ò
 
 (Becton Dickinson and
Co., Mountain View, CA). Thymocytes and spleen cells were
stained with antibodies to H-2K
 
b
 
 (E121.46; Seikagaku Kogyo,
Tokyo, Japan), Thy-1.2 (30-H12; Becton Dickinson and Co.),
TCR
 
ab
 
 (H57-597; provided by Dr. R. T. Kubo, National Jew-
ish Center for Immunology and Respiratory Medicine, Denver,
CO [26]), CD3 (145-2C11; provided by Dr. J. A. Bluestone,
The University of Chicago, IL [27]), CD4 (GK1.5; obtained
from Dr. N. Shinohara, Mitsubishi Kasei Institute for Life Sci-
ence, Machida, Japan, [28]), CD8 (53-6.7; obtained from Dr. N.
Shinohara [29]), CD25 (IL-2R
 
a
 
, 7D4; reference 30), CD44
(Pgp-1, NU5-50; Seikagaku Kogyo), B220 (RA3-6B2; Phar-
Mingen, San Diego, CA), and IgM (DAKO, Glostrup, Denmark).
 
ELISA for Measurement of Levels of Serum Ig.
 
For measurement
of IgM, IgG1, IgG2a, IgG2b, IgA, and IgE, 96-well flat-bottom
plates (Immuno Plate 430341; Nunc, Roskilde, Denmark) were
pre-coated with affinity-purified goat anti–mouse Ig
 
k
 
 (5 
 
m
 
g/ml,
100 
 
m
 
l/well; Bethyl Laboratories Inc., Montgomery, TX). For
 
1
 
Abbreviations used in this paper:
 
 ABC, avidin-biotin enzyme complex; B6,
C57BL/6; ED, embryonic day; ES, embryonic stem; HE, hematoxylin-
eosin; 
 
HSV
 
-
 
tk
 
, herpes simplex virus-thymidine kinase; MCH, Jcl:
MCH(ICR); TUNEL, TdT-mediated dUTP nick end labeling.
Figure 1. Structure of the relA targeting vector. The wild-type mouse
relA allele is shown at the top. The targeting vector is in the middle and
the predicted mutant allele is at the bottom. The area predicted to un-
dergo homologous recombination is indicated by the dotted lines. Exons
are indicated by closed boxes. The probes used for diagnostic DNA blot
analysis are also indicated at the top. Restriction enzyme sites: H, HindIII;
N, NcoI; P, PstI; Sm, SmaI; S, SphI.955 Doi et al.
Igk, plates were coated with affinity-purified rabbit anti-mouse
IgG (5 mg/ml, 100 ml/well; Southern Biotechnology Associates,
Inc., Birmingham, AL). Diluted serum samples and standard Ig
were added and bound Ig were detected with horseradish peroxi-
dase–labeled affinity-purified goat anti–mouse Ig isotype-specific
antibodies or an anti-k light chain-specific antibody (Southern
Biotechnology). o-Phenylendiamine solution (0.04%; Sigma) was
added to each well as a substrate. The optical density at 490 nm
was measured with a microplate reader (model 3550; Bio-Rad,
Hercules, CA).
IL-2 Bioassay. 3 3 105 spleen cells from transplanted mice
were plated in 96-well plates (200 ml per well). Con A (2 mg/ml;
Boehringer Mannheim GmbH, Mannheim, Germany), anti-CD28
(1 mg/ml; Caltag Laboratories, South San Francisco, CA), LPS
(20 mg/ml; Sigma), anti-IgM (60 mg/ml; Capel Research Prod-
ucts, Durham, NC), and PMA (10 ng/ml; Sigma) plus calcium
ionophore (100 ng/ml; Sigma) were added to the medium. For
anti-CD3 antibody stimulation, plates were pre-coated with the
antibody (10 mg/ml). After 18 h of culture, the supernatants were
collected for the assay. To measure the levels of IL-2, serially di-
luted culture supernatants were added to IL-2–dependent NRB cells
(5 3 103, reference 31) in 96-well plates. NRB cells were cul-
tured for 44 h and their proliferation was quantitated using a Cell-
Titer 96TM AQueous Non-Radioactive Cell Proliferation Assay
(Promega, Madison, WI) and a microplate reader (model 3550;
Bio-Rad). Recombinant human IL-2 (Takeda Chemical Indus-
tries, Osaka, Japan) was used as a standard.
Proliferation Assay. Conditions for cell culture and stimulation
were the same as for the IL-2 bioassay. After 48 h of culture, the
proliferation response was measured by uptake of [3H]thymidine
(New England Nuclear, Boston, MA) over a 16-h pulse. To de-
termine the percentage of cells in apoptosis during the course of
the proliferation assays, cells at 0, 24, 48, and 64 h after stimula-
tion were stained by the TdT-mediated dUPT nick labeling
(TUNEL) technique (32, 33), using an In Situ Cell Death Detec-
tion Kit (Boehringer Mannheim GmbH) and the results assessed
by FACScanÒ.
Results and Discussion
Requirement of RelA for Embryonic Development of the
Mouse. Mice heterozygous for a disrupted relA were nor-
mal and fertile, but no homozygous relA-deficient mice were
born from heterozygote mating. Sequential DNA blot analy-
sis and histological examination of embryos from timed
Figure 2. Liver degeneration and the absence of relA transcripts and
RelA protein in relA2/2 embryos. (A) Histological features of livers of
ED14.5 relA1/1 and relA2/2 embryos. In the liver of a relA1/1 em-
bryo, hepatocytes with large cell size and light nuclear staining are mixed
with the hematopoietic cells with dark nuclear staining. In the liver of
relA2/2 embryos, hepatocytes are disintegrated, while the hematopoi-
etic cells are apparently normal. Magnification is 240-fold. (B) RNA blot
analysis of ED13.5 relA1/1, 1/2, and 2/2 embryos. 10 mg of total
RNA were loaded per lane and analyzed with the relA, c-rel, relB, and p50
cDNA probes. relA transcripts were present in the relA1/1 and 1/2
embryos, but not in the relA2/2 embryos. The relA1/1, 1/2 and 2/2
embryos expressed similar amounts of c-rel and p50 transcripts. No relB
transcripts were detected in ED13.5 embryos (data not shown). (C) RelA
protein in ED13.5 relA1/1 and relA2/2 embryos. With rabbit anti-
RelA antibody and the ABC method, RelA protein is ubiquitously de-
tected in the relA1/1 embryo, but is completely absent in the relA2/2
embryo. Magnification is eightfold.956 Differentiation and Function of RelA-deficient Lymphocytes
matings of heterozygous mice were conducted. Until em-
bryonic day (ED) 13.5, all embryos were apparently normal
and homozygous mutants (2/2) were present in an ex-
pected ratio. On ED14.5, the relA2/2 embryos were still
present but some showed signs of abnormalities in their
liver (Fig. 2 A). On ED15.5, a portion of the embryos be-
came necrotic and were typed homozygous mutant (2/2),
while normal embryos were all wild type (1/1) or het-
erozygous (1/2). RNA blot analysis of relA1/1 embryos
from ED8.5 until birth as well as CCE ES cells showed the
presence of relA transcripts, while no relA transcripts could
be detected in relA2/2 embryos at any stage (Fig. 2 B).
Positive immunostaining with anti-RelA antibody corre-
lated with the presence of RNA transcripts, showing that
RelA proteins were present in almost all tissues of ED13.5
relA1/1 embryos, while no staining of relA2/2 embryos
(Fig. 2 C). Although a different vector construct was used
in our study, the generated RelA-deficient mice showed
the same phenotype as those of Beg et al. (11), indicating
that RelA is essential for embryonic development of the
mouse. In contrast to RelA-deficient mice, mice lacking
other NF-kB proteins are known to develop normally at
least until birth (12–14). The difference may simply reflect
the fact that RelA is expressed ubiquitously from an early
stage of development while the others are expressed in re-
stricted tissues from a much later stage (34, 35). Identifi-
cation of RelA responsive genes in developing embryos,
especially in the liver, should open new avenues for eluci-
dation of the function of NF-kB in embryonic development.
Transplantation of relA2/2 Fetal Liver Cells. During nor-
mal embryonic development, hematopoietic stem cells
emerge in the fetal liver on ED9.5 (36). To test whether
the RelA-deficient hematopoietic stem cells can develop in
the fetal liver and also whether they can differentiate to ma-
ture lymphocytes, fetal liver cells of ED13.5 embryos were
transplanted into irradiated SCID mice. Transplantation of
fetal liver cells not only from relA1/1 and 1/2 but also
from relA2/2 embryos greatly increased the number of
cells in the thymus, spleen and lymph nodes of SCID mice.
The numbers of cells in spleen and lymph nodes of the
mice transplanted with relA2/2 fetal liver cells were simi-
lar to those receiving either relA1/1 or 1/2 fetal liver
cells. The thymus from mice transplanted with relA2/2
fetal liver cells contained fewer cells than those with wild-type
or heterozygous fetal liver cells. The origin of the lympho-
cytes in transplanted mice was determined by testing the
expression of H-2Kb antigen. The fetal liver cells were
from crosses between 129 and B6, both of which express
H-2KbDb, while the recipient SCID themselves express
H-2KdDd. As shown in Fig. 3, .95% of lymphocytes of
mice transplanted with fetal liver cells expressed H-2Kb, in-
dicating that they were definitely of fetal liver origin. The
donor origin of the lymphocytes in transplanted mice with
fetal liver cells was further confirmed by the presence of dis-
rupted relA genes and the absence of relA transcripts (Fig. 4).
Figure 3. The fetal liver origin of lymphocytes in transplanted SCID
mice. By transplantation of the fetal liver from relA1/1, 1/2, or 2/2
ED 13.5 embryos into irradiated SCID mice, the number of lymphocytes
increased. Average numbers of the cells in the spleen, lymph nodes, and
thymus in groups of three mice receiving transplants are indicated above
the distribution plots. Staining in the presence and absence of mAb to H-2Kb
is indicated by solid and open curves, respectively. Flow cytometric anal-
ysis of spleen cells, lymph node cells, and thymocytes showed the expres-
sion of H-2Kb, indicating the fetal liver origin.
Figure 4. DNA and RNA
blot analyses of the spleen cells of
the transplanted SCID mice. (A)
DNA blot analysis. DNA di-
gested by PstI was analyzed with
a 59 franking probe (see Fig. 1);
the wild-type relA allele yielding
a 4.1-kb fragment, and the mu-
tant allele a 2.2-kb fragment. (B)
RNA blot analysis. Note the lack
of  relA transcripts in the spleen
cells of mice transplanted with
relA2/2 fetal liver cells. The
relA2/2,  1/1, and 1/2
spleen cells express similar
amounts of c-rel, relB, and p50
transcripts.957 Doi et al.
Thus, these results indicated that RelA-deficient hemato-
poietic stem cells can indeed develop in the fetal liver and
also proliferate in SCID mice.
Development of T and B Cells in the Absence of RelA.  To
test whether RelA-deficient stem cells can differentiate into
T and B cells, the cell surface markers on lymphocytes of
transplanted mice were examined. As shown in Fig. 5, the
relA2/2 hematopoietic stem cells differentiated to Thy-
11/TCRab1 /CD31/CD41 or CD81 T cells and IgM1/
B2201 B cells in the periphery, similarly to the relA1/1
and 1/2 stem cells. In addition, testing of the expression
of activation markers of T cells, IL-2Ra (CD25) and CD44
(Pgp-1), revealed 6.6 and 2.5% of relA2/2 spleen cells to
be positive, respectively, with no significant differences
from the relA1/1 or 1/2 cases (data not shown). The re-
sults with cells in lymph nodes were essentially identical to
those of spleens (data not shown). The relA2/2 thymuses
with much fewer cells than those of relA1/1 and 1/2,
showed reduction of the CD41/CD81 immature popula-
tion, which may have been caused by the absence of RelA.
Altogether, these results suggested that RelA is not neces-
sary for the maturation of lymphocytes or that the loss of
RelA function can be compensated for by other members
of the NF-kB family. In this regard, it was interesting to
note that none of the mice deficient in any NF-kB subunit,
whether RelA, c-Rel, RelB, or p50, showed abnormality in
the development of T cells and B cells. There is a vast
amount of evidence indicating the importance of NF-kB
in lymphocyte development (for review see references 1, 3,
37). Thus, it is most likely that the development of T and B
cells proceeds with certain combinations of NF-kB sub-
units and may not require the presence of specific NF-kB
dimers.
Reduced Production of IgG1 and IgA by relA2/2 B Cells.
As the RelA-deficient B and T cells matured normally, the
role of RelA in lymphocyte function was examined. To as-
sess B cell function, the levels of serum Ig isotypes in SCID
mice transplanted with fetal liver cells were measured (Fig.
6). The results showed that relA2/2 B cells were capable
of secreting Ig as well as switching classes of Ig isotypes.
The levels of total Ig and individual classes of IgM, IgG2a,
IgG2b, IgE, and Igk produced by relA2/2 B cells were
Figure 5. Surface antigen profiles of spleen cells and thymocytes of
SCID mice transplanted with ED13.5 fetal liver cells. Cells were exam-
ined by two-color staining using various combinations of antibodies. The
expression of H-2Kb by spleen cells confirms their fetal liver origin. As for
T cell markers, Thy-1, TCRab, CD3, CD4, and CD8 were examined
and as for B cell makers, IgM and B220 were examined. Even relA2/2
fetal liver cells develop normally to mature T and B cells in the trans-
planted SCID mice.
Figure 6. The serum Ig levels in SCID mice transplanted with fetal
liver cells. 4 wk after the transplantation, mice with relA2/2 fetal livers
were able to secrete Ig in their sera, with the total amount being compa-
rable to those with relA1/1 or relA1/2 cells, but the IgA and IgG1 lev-
els were found to be significantly lower. SCID mice secrete hardly detect-
able levels of any Ig isotypes. Open, striped, and closed circles correspond
to mice transplanted with relA1/1, 1/2, and 2/2 fetal liver cells, re-
spectively.958 Differentiation and Function of RelA-deficient Lymphocytes
comparable to those with relA1/1 or 1/2 B cells. Al-
though RelA was originally identified, together with p50,
as an enhancer binding protein for an Igk chain gene, sur-
prisingly the absence of RelA had no effect on the levels of
Igk production. The RelA-deficient B cells, however, pro-
duced 10-fold and 100-fold less IgG1 and IgA, respec-
tively, than the control B cells. Reduced production of
certain Ig classes has been also reported in mice deficient in
p50 (14) and c-Rel (12): IgG1, IgA, and IgE in the former
and IgG1 and IgG2a in the latter. Thus, each NF-kB
member is critically involved in the production of certain
Ig isotypes, presumably by regulating the transcription of Ig
genes directly and/or acting on various cytokine genes
which ultimately control Ig class switching and production.
In this regard, it is interesting to note that IgA reduction
has also been reported in IL-6-deficient mice (38) and that
the expression of IL-6 is controlled by RelA/p50 het-
erodimers (8).
IL-2 and IL-2Ra in relA2/2 T Cells. In T cells, the
RelA/p50 heterodimer has been reported to be a potent
transcription factor for the IL-2 gene after stimulation by
various agents (39). The relA2/2 spleen cells, however,
produced similar levels of IL-2 to relA1/1 or 1/2 spleen
cells after stimulation with Con A, anti-CD3, anti-CD31
anti-CD28, or PMA1calcium ionophore (Table 1). The
results were in contrast to those for c-Rel–deficient mice
which showed z50-fold reduction in IL-2 production af-
ter stimulation by anti-CD3, and anti-CD31anti-CD28
Table 1. Levels of IL-2 Production by Spleen Cells from SCID Mice Transplanted with Fetal Liver Cells in Response to Various Stimuli
relA genotype
of
fetal liver
donor*
Stimuli‡
Con A Anti-CD3 Anti-CD28
Anti-CD3 1
Anti-CD28
PMA 1 calcium
ionophore None
IL-2 levels
U/ml§
1/1 167 6 16.2i 63.7 6 10.3 5.7 6 0.84 446 6 19.8 361 6 69.8 4.5 6 1.42
1/2 146 6 18.5 42.8 6 5.27 5.2 6 0.82 448 6 10.9 312 6 26.1 2.0 6 0.05
2/2 118 6 16.8 60.3 6 8.11 6.5 6 1.08 402 6 88.0 276 6 42.3 2.4 6 0.32
None 1.5 6 0.66 3.4 6 1.03 2.3 6 0.62 5.2 6 1.84 6.5 6 1.32 1.4 6 0.32
*3 3 106 fetal liver cells from relA 1/1, 1/2, or 2/2 embryos were transplanted into irradiated SCID mice.
‡3 3 105 spleen cells were stimulated as described in the Materials and Methods.
§The levels of IL-2 were measured by bioassay using NRB cells (see the Materials and Methods).
iMean 6 SD. The results obtained from three mice were averaged.
Table 2. In Vitro Proliferation of Spleen Cells from SCID Mice Transplanted with Fetal Liver Cells in Response to Various Mitogenic Stimuli
relA genotype
of
fetal liver
donor*
Stimuli*
Con A Anti-CD3
Anti-CD3 1
Anti-CD28 LPS Anti-IgM
PMA 1 calcium
ionophore None
[3H]Thymidine uptake
cpm
1/1 19,328 6 3,771§ 46,465 6 4,898 94,775 6 2,612 18,336 6 2,924 15,571 6 2,003 73,837 6 2,261 305 6 73
(n 5 6)‡ (n 5 4) (n 5 3) (n 5 6) (n 5 4) (n 5 2) (n 5 6)
1/2 23,031 6 3,491 49,169 6 6,557 92,642 6 5,692 20,076 6 7,856 18,560 6 4,059 85,702 6 6,130 505 6 146
(n 5 9) (n 5 7) (n 5 6) (n 5 9) (n 5 7) (n 5 5) (n 5 9)
2/2 3,621 6960 18,343 6 3,030 18,865 6 4,575 4,717 6 1,026 5,879 6 1,076 20,863 6 6,150 403 6 168
(n 5 9) (n 5 7) (n 5 6) (n 5 9) (n 5 7) (n 5 5) (n 5 9)
None 381 6 145 911 6 352 860 6 215 807 6 285 689 6 285 1,707 6 734 298 6 75
(n 5 7) (n 5 5) (n 5 4) (n 5 7) (n 5 5) (n 5 3) (n 5 7)
*See Table 1.
‡Number of mice analyzed.
§Mean 6 SD.959 Doi et al.
and threefold reduction by the PMA1calcium ionophore.
Thus, it was strongly suggested that the main component of
the NF-kB transcription factor for the IL-2 gene in vivo is
c-Rel rather than RelA.
RelA has been reported to be involved also in the upreg-
ulation of IL-2Ra expression with stimulation by various
agents (40). Before stimulation, the levels of IL-2Ra on
relA2/2, 1/1, or 1/2 lymphocytes were similar to one
another as mentioned above. With stimulation by PMA1
calcium ionophore or Con A, the levels of IL-2Ra expres-
sion on relA2/2 T cells increased and did not significantly
differ from relA1/1 or relA1/2 T cells (data not shown).
The c-Rel-deficient T cells also showed no reduction in
the basal or induced expression of IL-2Ra (41). These ob-
servations suggest the following two possibilities: (a) neither
RelA nor c-Rel is required for the expression of IL-2Ra,
or (b) both can participate in the control of IL-2Ra expres-
sion and one works in the absence of the other. Identifica-
tion of binding subunits to the kB motif of IL-2Ra in the
absence of RelA or c-Rel and derivation of mice lacking
both RelA and c-Rel should sort out these possibilities.
Impaired Proliferative Response of relA2/2 Lymphocytes.
To further analyze the role of RelA in lymphocyte activa-
tion, spleen cells from mice transplanted with relA2/2 fe-
tal liver cells were stimulated with various agents. With both
T cell specific stimuli, Con A, anti-CD3 and anti-CD31
anti-CD28, and B cell–specific stimuli, LPS and anti-IgM,
relA2/2 spleen cells showed a much lower [3H]thymidine
uptake than relA1/1 or 1/2 spleen cells (Table 2). To
test whether this low response of relA2/2 spleen cells is
due to reduced cellular proliferation or to increased apop-
totic cell death, the percentages of cells in apoptosis during
the course of proliferation assays were determined. As
shown in Fig. 7, the percentages and the actual numbers of
apoptotic cells with relA2/2 were not significantly differ-
ent from the relA1/2 case. Although the number of viable
cells may not be as indicative as [3H]thymidine uptake be-
cause only a small component of the spleen cells can prolif-
erate in response to certain mitogenic stimuli, relA2/2
yielded constantly fewer viable cells than relA1/2. These
results indicate that RelA-deficient lymphocytes indeed have
an impaired proliferative response to various mitogens. As
the production of IL-2 and the expression of IL-2Ra were
normal in RelA-deficient T cells, the results suggested that
RelA is also involved in yet unidentified critical steps of pro-
liferative responses. Furthermore, RelA-deficient lympho-
cytes exhibited impaired responses to various stimuli whose
signals are transduced by distinctive pathways (42, 43).
Thus, RelA may be involved in each single pathway or in a
critical merging step downstream of these different path-
ways. Identification of RelA responsive genes involved in
proliferation should reveal the role of RelA in these re-
sponses. T and B cells of c-Rel–deficient mice have also
been found to demonstrate a defective proliferation re-
sponse to various stimuli, generally with severe reduction
(12). These results indicate that RelA and c-Rel are essen-
tial for certain steps of proliferation and that they cannot
compensate for each other. It is interesting to note that
Figure 7. Cells in apoptosis during the course of proliferation assays.
Spleen cells from mice transplanted with relA1/2 or 2/2 fetal liver cells
were stimulated with various mitogens as in Table 2. The percentages of
apoptotic cells were determined using the TUNEL technique with a
FACScanÒ (32, 33). The numbers of viable cells were determined by the
trypan blue exclusion test. At the beginning of stimulation, no cells were
in apoptosis. The averages and SD values from three independent experi-
ments are shown in the figure.960 Differentiation and Function of RelA-deficient Lymphocytes
SCID mice in the present investigation allowed light to be
cast on a number of the functions of RelA in the immune
system, despite the fact that the relA2/2 genotype is lethal
for embryos. Further study with in vitro and in vivo immu-
nization by T-dependent and -independent antigens should
facilitate clarification of RelA roles. In addition, since lym-
phocytes can be rescued from dying embryos by transplan-
tation of fetal liver cells as described here, mice lacking
multiple NF-kB proteins, such as RelA and c-Rel, or
RelA and RelB, should now be testable for their actions
exerted in concert.
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relA2/2 lymphocytes showed an impaired proliferative
response to PMA1calcium ionophore in this study while
c-rel2/2 lymphocytes respond normally to this agent (12).
Presumably, the involvement of RelA in proliferative re-
sponses is thus wider. Furthermore, relA2/2 embryonic
fibroblasts also showed reduced proliferation after PMA1
calcium ionophore stimulation, down to 30% of the levels
of their relA1/1 or 1/2 counterparts (data not shown).
As expression of relA is not restricted to lymphocytes, in
contrast to that of c-rel (44), this also suggests a role in a
wider range of biological processes.
In conclusion, transplantation of fetal liver cells into
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